Home » Stocks » Tenax Therapeutics

Tenax Therapeutics, Inc. (TENX)

Stock Price: $1.32 USD -0.08 (-5.40%)
Updated Aug 4, 2020 10:16 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 16.59M
Revenue (ttm) n/a
Net Income (ttm) -9.43M
Shares Out 12.62M
EPS (ttm) -1.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $1.32
Previous Close $1.39
Change ($) -0.08
Change (%) -5.40%
Day's Open 1.37
Day's Range 1.29 - 1.38
Day's Volume 155,775
52-Week Range 0.25 - 2.68

More Stats

Market Cap 16.59M
Enterprise Value 11.77M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 12.62M
Float 8.08M
EPS (basic) -1.41
EPS (diluted) -1.40
FCF / Share -1.16
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 617,491
Short Ratio 0.08
Short % of Float 0.16%
Beta 2.21
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.62
Revenue n/a
Operating Income -9.56M
Net Income -9.43M
Free Cash Flow -8.09M
Net Cash 4.83M
Net Cash / Share 0.38
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -68.63%
ROE -137.10%
ROIC 2,768.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.22*
(220.91% upside)
Low
4.00
Current: $1.32
High
4.45
Target: 4.22
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----0.050.291.230.420.320.01
Revenue Growth-----82.93%-76.6%197.33%28.75%3759.08%-
Gross Profit----0.050.161.190.360.100.01
Operating Income-8.56-6.89-9.21-52.65-14.82-16.61-5.19-8.22-10.56-10.20
Net Income-8.39-14.14-8.84-43.92-14.08-19.54-9.42-15.71-10.45-10.51
Shares Outstanding6.201.561.411.411.400.470.080.060.060.05
Earnings Per Share-1.35-9.04-6.27-31.24-10.00-54.20-133.60-281.40-180.00-216.00
Operating Cash Flow-7.56-5.50-12.14-15.87-9.75-9.26-4.92-8.28-8.40-8.59
Capital Expenditures--0.01-0.07--0.01-0.01-0.01-0.24-0.24
Free Cash Flow-7.56-5.51-12.15-15.80-9.75-9.27-4.93-8.29-8.64-8.82
Cash & Equivalents5.4012.867.7313.2817.1358.320.781.880.950.63
Total Debt0.06---0.100.353.051.424.510.06
Net Cash / Debt5.3412.867.7313.2817.0357.97-2.270.46-3.550.57
Assets6.3713.349.8923.3482.9193.433.184.142.923.53
Liabilities2.591.571.016.2012.4810.544.964.496.651.40
Book Value3.7711.778.8817.1470.4382.89-1.78-0.35-3.722.13
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Tenax Therapeutics, Inc.
Country United States
Employees 9
CEO Anthony A. DiTonno

Stock Information

Ticker Symbol TENX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TENX

Description

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical trial of levosimendan for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.